# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell...
IMP761 is designed to enhance the "brake" function of LAG-3 on T cells to restore balance to the immune system and addr...
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to ...
Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limite...
ZAPP: 40% | Zapp Electric Vehicles shares are trading higher after the company announced that it entered into a new standby equ...
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Ke...